Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, United States
Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States; Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, United States
Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States
Asa A Brockman
Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States
Kirsten E Diggins
Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States
Allison R Greenplate
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, United States
Kyle D Weaver
Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, United States
Reid C Thompson
Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, United States
Lola B Chambless
Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, United States
Bret C Mobley
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, United States
Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States; Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, United States
Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, United States
A goal of cancer research is to reveal cell subsets linked to continuous clinical outcomes to generate new therapeutic and biomarker hypotheses. We introduce a machine learning algorithm, Risk Assessment Population IDentification (RAPID), that is unsupervised and automated, identifies phenotypically distinct cell populations, and determines whether these populations stratify patient survival. With a pilot mass cytometry dataset of 2 million cells from 28 glioblastomas, RAPID identified tumor cells whose abundance independently and continuously stratified patient survival. Statistical validation within the workflow included repeated runs of stochastic steps and cell subsampling. Biological validation used an orthogonal platform, immunohistochemistry, and a larger cohort of 73 glioblastoma patients to confirm the findings from the pilot cohort. RAPID was also validated to find known risk stratifying cells and features using published data from blood cancer. Thus, RAPID provides an automated, unsupervised approach for finding statistically and biologically significant cells using cytometry data from patient samples.